Work to Commence at Waste Rock Dump
Alba Mineral Resrcs. (ALBA.L) Clogau-St David’s Gold Mine Update
Genflow Biosciences – Intention to Float on the London Stock Exchange
Genflow Biosciences Plc (“Genflow” or ” the Company”), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with
Tally Ltd Founder Director Loan & Placing, and TVR
Tally Ltd, the money innovator that developed the non-fiat full-reserve savings and payments platform and physical-gold digital money, tally®, is pleased to provide the following update to shareholders.
TALLY LTD Activities Summary 2021, Q4 Update and AGM Results
31 December 2021 Tally Ltd, the money innovator that developed the Tally full-reserve non-fiat banking platform and physical-gold digital money, tally®, is pleased to update shareholders about the Company’s activities
TALLY LTD Final Results & AGM has been set for 30 December 2021
Tally Ltd, the non-fiat money innovator and developer and operator of the Tally full-reserve banking platform and physical-gold digital money, tally®, is pleased to present its audited financial results for
Open Orphan PLC (ORPH.L) Imutex Vaccine Phase I Study Results
mutex to present positive Phase I clinical study results for AGS-v PLUS mosquito vaccine candidate AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results
Open Orphan PLC (ORPH.L) £5.1m RSV Human Challenge Study Contract Win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) £1.5m Contract renewal for Venn Life Sciences
£1.5m Contract renewal for Venn Life Sciences with a major global pharmaceutical client
Open Orphan PLC (ORPH.L) Directorate Change
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment
How one company is testing vaccines through intentional infection
Open Orphan Executive Chairman Cathal Friel joins Yahoo Finance Live to discuss how his company is testing vaccines through intentional infection.
Oxford Nanopore valued at £4.93bn as shares soar in London debut
Investors snapped up shares in biotech company Oxford Nanopore after its IPO this morning, with the shares soaring 45 per cent.
